Cargando…
Syntheses of Thailandepsin B Pseudo‐Natural Products: Access to New Highly Potent HDAC Inhibitors via Late‐Stage Modification
New Thailandepsin B pseudo‐natural products have been prepared. Our synthetic strategy offers the possibility to introduce varying warheads via late stage modification. Additionally, it gives access to the asymmetric branched allylic ester moiety of the natural product in a highly diastereoselective...
Autores principales: | Brosowsky, Jana, Lutterbeck, Monika, Liebich, Amelie, Keller, Manfred, Herp, Daniel, Vogelmann, Anja, Jung, Manfred, Breit, Bernhard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756392/ https://www.ncbi.nlm.nih.gov/pubmed/32725698 http://dx.doi.org/10.1002/chem.202002449 |
Ejemplares similares
-
Thailandepsin A
por: Wang, Cheng, et al.
Publicado: (2011) -
Thailandepsins are new small molecule class I HDAC inhibitors with potent cytotoxic activity in ovarian cancer cells: a preclinical study of epigenetic ovarian cancer therapy
por: Wilson, Andrew J, et al.
Publicado: (2012) -
Histone deacetylase inhibitor thailandepsin-A activates Notch signaling and suppresses neuroendocrine cancer cell growth in vivo
por: Jang, Samuel, et al.
Publicado: (2017) -
μ-Bromido-dibromido-μ-hydroxido-bis[(4S)-2-halo-6-(4-isopropyl-4,5-dihydrooxazol-2-yl)pyridine]dicopper(II) (halo: Cl/Br = 3:1)
por: Laungani, Andy Ch., et al.
Publicado: (2007) -
Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer - overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression
por: Müller, Berit Maria, et al.
Publicado: (2013)